Company news

Argenica Therapeutics Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

New Mechanism Findings Offer Insights Into Phase 2 Signal

October 19, 2026

New Mechanism Findings Offer Insights Into Phase 2 Signal

October 19, 2026

Notice of Annual General Meeting/Proxy Form

October 19, 2026

Change of Director's Interest Notice

September 28, 2026

AGM Date & Closing Date for Director Nominations

September 22, 2026

Concussion Data Selected for Neurotrauma Congress

September 14, 2026

Appendix 4E & Annual Report to 30 June 2026

August 26, 2026

Appendix 4G & Corporate Governance Statement

August 26, 2026

Notification of cessation of securities - AGN

August 13, 2026

ARG007 Shows Significant Neuroprotection in Concussion Study

July 15, 2026

ARG007 (Xaranetide) Completes All Three FDA Requested Assays

June 10, 2026

WHO Confirms Xaranetide as INN for ARG-007

June 9, 2026

IND Application Advanced With Successful Completion of Assay

May 20, 2026

Clinical Advisory Committee Established to Advance Phase 2b

May 13, 2026

Presentations at European Stroke Organisation Conference

March 25, 2026

Argenica Receives $3.97m R&D Tax Incentive Cash Rebate

March 16, 2026

Half Yearly Report and Accounts

February 10, 2026

Successful Applicaton for EMA Paediatric Waiver

February 1, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 27, 2026

AI Analysis Reveals Efficacy In Severe Stroke Patients

December 10, 2025

Positive TNK Study Results Fulfil Key FDA Requirement

December 3, 2025

ARG-007 Efficacious Dose Validated in New Preclinical Study

November 24, 2025

Phase 2 Trial Promising Improvements in Functional Outcomes

October 14, 2025

Topline Phase 2 Trial Results of ARG-007 in AIS Patients

September 2, 2025

Trading Halt

August 31, 2025

Appendix 4E & Annual Report to 30 June 2025

August 28, 2025

Argenica Receives IND Feedback From FDA

August 13, 2025

Argenica Awarded Federal Government Funding

June 20, 2025

Argenica to Progress Clinical Development in TBI

June 17, 2025

Update on Investigational New Drug Application

June 9, 2025

New US Patent for Surgical Stroke

May 21, 2025

Last Patient Dosed in Phase 2 Stroke Trial

April 10, 2025

Updated - Main TBI Injury Study Annoucement

February 3, 2025

ARG-007 Shows Significant Neuroprotection in Main TBI Study

February 3, 2025

Positive DSMB Safety Outcome & Phase 2 Trial Progress Update

January 29, 2025

Phase 2 Stroke Clinical Trial Update

December 9, 2024

$2.76m R&D Tax Incentive Cash Rebate Received for FY24

November 20, 2024

Quarterly Activities/Appendix 4C Cash Flow Report - updated

October 31, 2024

FDA Grants ODD & RPDD for Second Drug in Treatment of HIE

October 30, 2024

Positive Results in Key IND Enabling Studies

September 25, 2024

Appendix 4E & Annual Report to 30 June 2024

August 28, 2024

ARG-007 Reduces Effects of TBI in Preclinical Study

May 14, 2024

DSMB Confirms Safety of First Patients Dosed

April 28, 2024

Argenica Successfully Completes $12.0m Placement

April 11, 2024

Patient Dosing Milestone Achieved in Phase 2 Stroke Trial

April 9, 2024

First Patient Dosed in Phase 2 Stroke Trial of ARG-007

March 27, 2024

FDA Grants Rare Pediatric Disease Designation For HIE

March 24, 2024

Phase 2 Manufacturing Completed & Trial Update

February 11, 2024

Older news releases →

Decks

The 5 newest of 28 decks. Every deck is listed under its year.